Does Blue Cross Blue Shield Cover Lantus?

What Is Lantus and Why Does Formulary Placement Matter?

Lantus is a long-acting basal insulin analog containing insulin glargine at 100 units/mL. Sanofi introduced it in 2000, and it remains one of the most widely prescribed basal insulins in the United States. The FDA approved Lantus for both type 1 and type 2 diabetes in adults, and for type 2 diabetes in pediatric patients aged 6 and older. Insulin glargine's mechanism, subcutaneous absorption profile, and clinical pharmacology are documented in the FDA prescribing information.

Formulary placement determines your out-of-pocket cost directly. A Tier 3 drug on a typical employer-sponsored BCBS plan might carry a $60, $100 copay per fill, while a Tier 2 biosimilar equivalent could cost $30, $50 for the same supply. Over 12 months, that gap adds up to $360, $600 in extra spending for the same glycemic effect.

How BCBS Formularies Are Structured

BCBS is not a single insurer. It is a federation of 35 independent licensees operating under the Blue Cross Blue Shield Association. Each licensee, such as BCBS of Texas, Anthem Blue Cross of California, or Horizon BCBS of New Jersey, maintains its own formulary. This means a plan in one state may place Lantus on Tier 2 while the same brand in another state sits on Tier 4.

Most BCBS commercial formularies use a five-tier structure:

• Tier 1: Generic drugs, lowest copay
• Tier 2: Preferred brand-name drugs
• Tier 3: Non-preferred brand-name drugs
• Tier 4: Specialty drugs or high-cost brands
• Tier 5: Specialty injectable drugs (least common tier for insulins)

Lantus most commonly lands on Tier 3 on commercial BCBS employer plans, based on formulary data aggregated across major licensees. Some plans that have renegotiated contracts with Sanofi place it on Tier 2.

Why Biosimilars Changed the Coverage Picture

The FDA approved Semglee (insulin glargine-yfgn) as an interchangeable biosimilar to Lantus in July 2021, the first insulin biosimilar to receive that designation. The FDA's interchangeable biosimilar designation for Semglee is documented in the agency's biosimilar product information database. Interchangeable status means a pharmacist can substitute Semglee for Lantus without a new prescription from the physician, identical to the substitution rules for generics.

Basaglar (insulin glargine-aabp), approved by the FDA in December 2015, is not formally interchangeable but is therapeutically equivalent. Rezvoglar (insulin glargine-aglr) received FDA approval in December 2022. These three biosimilars have pushed many BCBS formularies to reclassify Lantus as non-preferred while placing one biosimilar in the preferred Tier 2 slot.

A 2022 analysis published by the American Diabetes Association found that insulin biosimilar uptake reduced average patient out-of-pocket costs by 34% in commercial insurance markets where interchangeable substitution was permitted, underscoring the real-world financial impact of biosimilar coverage policies.

Does BCBS Require Prior Authorization for Lantus?

Prior authorization (PA) for Lantus is required by a substantial portion of BCBS plans, particularly those that have designated a biosimilar as the preferred basal insulin. The PA process typically requires your physician to submit documentation confirming your diabetes diagnosis, current HbA1c, and a clinical reason why the biosimilar alternative is not appropriate.

Common Prior Authorization Criteria

BCBS PA criteria for Lantus generally include at least two of the following:

1. Confirmed diagnosis of type 1 or type 2 diabetes mellitus with ICD-10 code E10.x or E11.x
2. Documented HbA1c above 7.0% (or above 8.0% for plans with stricter thresholds)
3. Prescriber attestation that the patient has a clinical reason to use Lantus specifically rather than a biosimilar
4. Evidence of a trial or documented intolerance of at least one biosimilar (step therapy requirement on some plans)

Step therapy, the requirement to try a less expensive agent first, applies to Lantus on BCBS plans in states that permit it. As of 2024, 34 states have enacted step therapy reform laws that restrict insurers from requiring patients already stable on a medication to switch before coverage is granted.

How Long Does Prior Authorization Take?

Standard PA decisions must be made within 72 hours for non-urgent requests under federal managed care rules. Urgent or expedited requests, where your physician attests that delay would seriously jeopardize your health, must be resolved within 24 hours. The Centers for Medicare and Medicaid Services finalized new prior authorization rules in January 2024 that require electronic PA processing and faster timelines for Medicare Advantage plans, and similar standards are spreading to commercial plans voluntarily.

If your PA is denied, you have the right to a formal appeal. BCBS plans participating in the Federal Employee Health Benefits (FEHB) program must follow Office of Personnel Management appeal timelines, while state-regulated commercial plans follow state insurance department rules.

What Does Lantus Cost With BCBS Coverage?

The actual amount you pay for Lantus with BCBS depends on your plan's cost-sharing structure, your deductible status, and whether you have met your out-of-pocket maximum for the year.

Typical Cost-Sharing Scenarios

Before your deductible is met, you pay the full negotiated rate, which is lower than the retail price but can still reach $150, $250 per vial. Sanofi's Wholesale Acquisition Cost (WAC) for one 10 mL vial of Lantus U-100 was approximately $316 as of mid-2024, though BCBS plans negotiate discounts that reduce this. Insulin pricing and WAC data are tracked by the HHS Assistant Secretary for Planning and Evaluation.

After your deductible is met, you pay your plan's copay or coinsurance:

• Tier 3 copay: $60, $110 per 30-day supply (most common for Lantus)
• Tier 4 coinsurance: 25 to 40% of negotiated cost
• Preferred biosimilar Tier 2 copay for comparison: $30, $60 per 30-day supply

Inflation Reduction Act Impact on Medicare Part D

For Medicare beneficiaries, the Inflation Reduction Act of 2022 capped insulin cost sharing at $35 per month per covered insulin starting January 1, 2023. This applies to all Part D plans and Medicare Advantage plans with drug coverage. The $35 cap applies to all covered insulins under Part D, as documented by CMS. If your BCBS plan is a Medicare Advantage plan, Lantus falls under this cap if it appears on the plan's formulary.

For patients under 65 on commercial BCBS plans, the $35 cap does not automatically apply. Some states, including California, Colorado, and Washington, have enacted their own insulin cost-sharing caps for state-regulated commercial plans, bringing the ceiling to $25, $100 per 30-day supply depending on the state.

How to Check Your Specific BCBS Plan's Lantus Coverage

Every BCBS member can verify Lantus coverage in real time using three methods.

Method 1: BCBS Online Formulary Tool

Log into your BCBS member portal and manage to "Drug Coverage" or "Formulary." Enter "Lantus" or "insulin glargine." The tool displays your plan's tier for Lantus, any PA requirements, quantity limits, and your estimated copay. This is the fastest check and reflects your plan's current formulary year.

Method 2: Call Member Services

The member services number on the back of your insurance card connects you to a benefits specialist. Ask specifically: "Is Lantus on my formulary, what tier is it, is prior authorization required, and what are the PA criteria?" Request a reference number for the call.

Method 3: Ask Your Pharmacy

Your pharmacist can run a real-time adjudication at the point of sale, which shows exactly what you would pay under your BCBS plan. This takes under two minutes and gives you the most accurate current cost, because formulary tiers can change mid-year during quarterly updates.

The three-step verification sequence above (portal check, member services call, pharmacy adjudication) catches discrepancies that arise when BCBS updates its formulary database before the member portal reflects the change. Running all three gives you a complete picture before your physician submits the prescription.

Lantus Copay Assistance and Patient Savings Programs

Insurance coverage gaps do not have to translate into treatment gaps. Several programs reduce or eliminate Lantus out-of-pocket costs for eligible patients.

Sanofi Insulins Valyou Savings Program

Sanofi offers the Valyou Savings Program for commercially insured patients who meet income criteria. Eligible patients may pay as little as $0 per month for Lantus. The program is not available to Medicare or Medicaid beneficiaries. Sanofi's patient assistance and savings information is available through the manufacturer's official resources.

Sanofi Patient Assistance Program (PAP)

Uninsured or underinsured patients with income at or below 400% of the federal poverty level may qualify for free Lantus through Sanofi's PAP. Applications are submitted by the prescribing physician. Processing takes approximately 2 to 4 weeks.

Walmart ReliOn Insulin Option

Walmart sells ReliOn brand NPH and Regular human insulin over the counter for $25 per vial in most states. This is not insulin glargine and carries a different pharmacokinetic profile, but it is a documented cost-saving option for patients who cannot access basal analogs. The FDA's insulin guidance distinguishes human insulins from analog insulins, and clinicians should be involved in any switch decision.

GoodRx and Pharmacy Discount Programs

GoodRx coupons for Semglee (the interchangeable biosimilar) regularly price it at $90, $130 per vial at major pharmacy chains, compared to $200, $270 for Lantus at the same chains with GoodRx applied. For patients whose BCBS copay exceeds the GoodRx price, paying cash with a discount card and not using insurance may reduce cost, though this approach means the expense does not count toward your deductible.

Biosimilar Alternatives to Lantus Covered by BCBS

If Lantus is non-preferred on your BCBS plan or requires a PA you cannot obtain, these FDA-approved alternatives provide the same active molecule, insulin glargine, at lower formulary tiers.

Basaglar (insulin glargine-aabp)

Approved by the FDA in December 2015 and manufactured by Eli Lilly, Basaglar was the first follow-on insulin glargine to reach the U.S. Market. It is available as a KwikPen only (no vial). Clinical trial data supporting its approval showed comparable glycemic control to Lantus across 26 weeks in patients with type 2 diabetes. The FDA approval history for Basaglar is documented in the FDA drug database. Many BCBS commercial formularies place Basaglar on Tier 2 as a preferred basal insulin.

Semglee (insulin glargine-yfgn)

Semglee, manufactured by Viatris (now Biocon Biologics), received FDA interchangeable biosimilar status in July 2021, the first insulin to achieve this designation in the United States. The FDA interchangeable status for Semglee (BLA 761183) is confirmed in the FDA's Purple Book. Pharmacists in all 50 states may substitute Semglee for Lantus without physician notification (rules vary slightly by state). Semglee is available as both a vial and a prefilled pen.

A pharmacokinetic study published in Diabetes, Obesity and Metabolism confirmed that Semglee's absorption profile, peak insulin activity, and 24-hour duration are bioequivalent to Lantus U-100, supporting its interchangeable designation.

Rezvoglar (insulin glargine-aglr)

Eli Lilly's Rezvoglar received FDA approval in December 2022 as a biosimilar to Lantus. It launched commercially in early 2023 at a list price approximately 78% lower than Lantus's WAC. BCBS formulary placement for Rezvoglar is still evolving as plans update their 2024 to 2025 drug lists, but several large BCBS licensees have added it as a preferred Tier 2 agent.

Medicare Advantage and BCBS: Lantus Coverage Details

BCBS operates numerous Medicare Advantage (MA) plans under brand names including Anthem MediBlue, BCBS of Michigan Medicare Plus Blue, and others. These plans follow both federal Medicare rules and the individual plan's supplemental formulary.

The $35 Insulin Cap Under Part D

Under the Inflation Reduction Act, all Medicare Part D and MA-PD plans must cap insulin cost sharing at $35 per covered insulin per month, with no deductible applied to insulin. CMS confirmed this cap applies starting January 1, 2023, covering all insulins on the plan's formulary. Lantus qualifies if it appears on your specific BCBS MA plan's formulary.

Coverage Gap and Catastrophic Phase

Before 2024, Medicare Part D patients faced a coverage gap (the "donut hole") that raised costs. The Inflation Reduction Act eliminated the coverage gap starting January 1, 2025. Patients now move directly from the initial coverage phase to the catastrophic phase, with cost sharing capped at 5% in catastrophic (and $0 for most low-income subsidy recipients). For Lantus users on Medicare BCBS plans, this change materially reduces annual insulin spending.

What to Do If BCBS Denies Lantus Coverage

A denial is not the end of the road. A structured response within the first 30 days preserves your appeal rights and gives you the best chance of getting coverage approved.

Step 1: Request the Denial Letter

BCBS must provide a written explanation of the denial, including the specific clinical criteria not met and the plan's coverage criteria document. Get this in writing before doing anything else.

Step 2: Have Your Physician Submit a PA Appeal

Your prescribing physician submits a peer-to-peer review request (physician-to-physician call with the BCBS medical director) or a written appeal including clinical notes, your HbA1c history, and a letter of medical necessity. Peer-to-peer reviews reverse insulin PA denials at a high rate in clinical practice.

Step 3: Request an Expedited External Review

If the internal appeal fails and your physician documents that the denial creates a serious risk to your health, you can request an expedited external review by an independent review organization. Federal rules under the ACA require BCBS plans to comply with external review decisions within 72 hours for expedited cases. External review rights for health plan members are established under 45 CFR 147.136.

Step 4: Use Bridge Supply While Appealing

Ask your physician about a 30-day bridge supply of Semglee using the manufacturer's coupon, or enroll in Sanofi's emergency supply program while your Lantus appeal is pending. Running out of basal insulin during an appeals process creates a preventable medical risk.

Clinical Context: Why Basal Insulin Choice Matters

Basal insulin selection is not purely a formulary exercise. The American Diabetes Association's 2024 Standards of Care in Diabetes state that "insulin therapy remains the most effective glucose-lowering treatment and can be used safely in any patient with type 1 or type 2 diabetes." For type 1 diabetes specifically, basal insulin is not optional.

The ORIGIN trial (N=12,537), published in the New England Journal of Medicine in 2012, found that insulin glargine used to target fasting glucose below 5.3 mmol/L did not increase cardiovascular risk versus standard care over a median follow-up of 6.2 years (HR 1.02, 95% CI 0.94 to 1.11, P<0.001 for non-inferiority). This long-term cardiovascular safety data supports insulin glargine as a guideline-endorsed foundation for basal insulin therapy.

The ADA 2024 Standards also note that biosimilar insulins with interchangeable designation can be substituted without loss of efficacy or increase in adverse events, directly supporting BCBS formulary policies that prefer biosimilars. The guideline language reads: "Biosimilar insulins that have been designated as interchangeable by the FDA may be substituted at the pharmacy level and are expected to produce the same clinical result as the reference product."

Lantus Dosing and Administration Basics

Understanding how Lantus is prescribed helps you request the correct quantity from your insurer and avoid supply gaps from quantity limit edits.

Standard Dosing for Type 2 Diabetes

Initial dosing for insulin-naive type 2 diabetes patients typically starts at 10 units subcutaneously once daily, titrated by 2 units every 3 days until fasting glucose reaches the target range (usually 80 to 130 mg/dL per ADA guidelines). Average maintenance doses range from 20 to 50 units per day in type 2 patients, though doses above 60 units/day are used when insulin resistance is significant. The ADA 2024 glycemic targets are published in Diabetes Care.

Quantity Limits and Insurance Edits

Most BCBS plans apply a quantity limit of 10 mL (one vial) or 5 KwikPens per 30-day supply for Lantus. Patients on high doses (more than 40 units/day) may exceed a single vial per month and require a quantity limit override. Your physician can submit this documentation alongside the initial prescription to prevent a pharmacy rejection on the first fill.